Intranasal oxytocin is one of 52 small molecule programs targeting Oxytocin. It is currently in Phase 2.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
350 competitors in Treatment
Intranasal oxytocin
Emtriva
Theo-Dur
Levulan
Lamprene
Foscavir
Hivid
Valium
Clomid
Aurlumyn
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details